Sanofi’s GPRC5D monoclonal antibody earns ODD in US for multiple myeloma

Emcure Pharmaceuticals, Sanofi India ink distribution agreement to broaden reach of Sanofi's oral anti-diabetic drugs

Thermo Fisher Scientific to acquire Sanofi’s steriles manufacturing site in Ridgefield, New Jersey

Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers

Sanofi exercises license extension option to Nurix’s STAT6 program

his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days

Sanofi acquires US biopharma firm Blueprint Medicines for $9.1 billion

Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio

Sanofi India posts 27% growth in operating profits in Q1 2025

Standalone profit from operations for the quarter were Rs. 162 crores

Sanofi Consumer Healthcare India Q1 PAT up 12.9%

The Q1 2025 also witnessed a successful launch of Allegra D

Sanofi India MD Rodolfo Hrosz to step down on April 30

The board of directors accepted Hrosz’s resignation and expressed appreciation for his significant contributions during his tenure

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD

Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)

Sanofi India declares 8% growth in net sales for Q4-2024

Standalone profit from operations for Q4-2024 were Rs. 108 crore